Trial | NCT04530409  Report issue

Official Title

Timing of Corticosteroids in COVID-19, II. Post COVID-19 Follow-up

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Active, not recruiting

  • Study Participants

    752
Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has features in common with a rare haematological condition called haemophagocytic lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune suppression during the early phase of the viral infection might allow increased viral replication and aggravate the disease.

The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so activation of histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2.

Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality.
Study Started
Mar 20
2021
Primary Completion
Nov 01
2021
Study Completion
Oct 15
2023
Anticipated
Last Update
Sep 06
2023

Drug Early-Corticosteroids

early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers

  • Other names: Dexamethasone, Methylprednisolone

Early CS Experimental

early use of dexamethasone as early as the laboratory confirmation of inflammation.

Late CS No Intervention

Dexamethasone is to be used lately upon the deterioration of cases i.e. sPO2 < 92%

Criteria 

Inclusion Criteria:

any case with COVID-19 more than or equal to 18 years
mild and moderate severity

Exclusion Criteria:

Severe to critical COVID-19
Any contra-indication for the interventional drug
Mentally disabled cases
No Results Posted